The online version of this article (https://doi.org/10.1007/s11239-019-01891-0) contains supplementary material, which is available to authorized users.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Routine thromboprophylaxis (TP) in newly-diagnosed multiple myeloma (NDMM) patients comprises either aspirin for standard risk patients or low molecular weight heparin for high risk patients. Studies using DOACs in cancer patients include few with myeloma. The aim of this feasibility clinical trial was to establish the foundations for creating a multicentre trial and identify any safety concerns with apixaban. Patient perspectives were sought. NDMM patients were stratified according to VTE risk and randomised to either standard TP or apixaban 2.5 mg BD and reviewed every 3 weeks throughout their chemotherapy. Two focus groups were carried out on 2 occasions at King’s College Hospital and Guy’s Hospital, London. Each lasted an hour, were recorded, transcribed and themes explored using NVivo 11. Ten patients were recruited, 2 considered high risk and received apixaban and 8 standard risk; 4 randomised to aspirin and 4 to apixaban. Five patients and 2 carers participated in the focus groups. There were no major bleeding or VTE events. Patients were not aware of the thrombotic risk associated with cancer. There is a lack of both written and verbal information on this topic. Myeloma patients were happy to be included in more than one trial simultaneously. Our study provides information on the difficulties facing physicians and patients on obtaining evidence of the safety of DOACs in the context of myeloma. Despite patients being happy to co-recruit into thromboprophylaxis trials along with chemotherapy trials this is not current practice.
EudraCT Number: 2015-002668-18
Supplementary material 1 (DOCX 18 kb)11239_2019_1891_MOESM1_ESM.docx
Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-Marchant K, Hussein MA (2004) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer 101(3):558–566 CrossRef
Fotiou D, Gerotziafas G, Kastritis E, Dimopoulos MA, Terpos E (2016) A review of the venous thrombotic issues associated with multiple myeloma. Expert Rev Hematol 9(7):695–706 CrossRef
Palumbo A, Rajkumar SV, Dimopoulos M, Richardson PG, San Miguel J, Barlogie B et al (2008) Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 22(2):414–423 CrossRef
Bradbury CA, Jenner MW, Striha A, Cook G, Pawlyn C, Jones JR et al (2017) Thrombotic events in patients with myeloma treated with immunomodulatory drugs: results of the myeloma XI study. Blood J 130:553
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A et al (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380(8):711–719 CrossRef
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T et al (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380(8):720–728 CrossRef
Noble S, Prout H, Nelson A (2015) Patients’ Experiences of LIving with CANcer-associated thrombosis: the PELICAN study. Patient Prefer Adherence 24(9):337–345 CrossRef
Khorana AA (2010) Venous thromboembolism and prognosis in cancer. Thromb Res 125(6):490–493 CrossRef
Rodeghiero F, Tosetto A, Abshire T, Arnold D, Coller B, James P et al (2010) ISTH/SSC bleeding assessment tool: a standardized questionnaire and a proposal for a new bleeding score for inherited bleeding disorders. J Thromb Haemost 8(9):2063–2065 CrossRef
Zangari M, Fink L, Zhan F, Tricot G (2011) Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens. Clin Lymphoma Myeloma Leuk 11(2):228–236 CrossRef
Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G (2015) Assessing patients’ anticoagulation preferences for the treatment of cancer-associated thrombosis using conjoint methodology. Haematologica 100(11):1486–1492 CrossRef
- What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial
Jignesh P. Patel
Lara N. Roberts
Raj K. Patel
- Springer US
Neu im Fachgebiet Kardiologie
Mail Icon II